Janux Therapeutics (JANX) investor relations material

Executive summary

• Entered an exclusive worldwide license and collaboration agreement with Bristol Myers Squibb (BMS) to develop a novel tumor-activated therapeutic for solid tumors, leveraging proprietary T cell engager technology.

• Janux will conduct preclinical development up to IND submission; BMS will hold the IND and lead subsequent development and commercialization globally.

• Achieved milestone payment from Bristol Myers Squibb collaboration.

• Advanced prostate cancer franchise with ongoing JANX007 Phase 1b enrollment and initiation of JANX014 clinical evaluation.

• Discontinued JANX008 after Phase 1a, reallocating resources to other pipeline programs.

Significant events and developments

• The agreement grants BMS an exclusive, sublicensable, royalty-bearing license to exploit Janux's technology for the specified therapeutic, with Janux retaining limited rights for its development activities.

• Janux will support BMS through completion of the first Phase 1 clinical study, after which BMS assumes full responsibility for further development and commercialization.

• The collaboration includes a joint steering committee for governance, with BMS holding final decision-making authority on most development matters after good faith discussions.

• $35 million milestone payment triggered by development candidate nomination under Bristol Myers Squibb collaboration.

• Appointment of William Go, M.D., Ph.D. as Chief Medical Officer.

Capital allocation and financing

• Janux receives a $15 million upfront payment and a $35 million milestone payment upon selection of the first development candidate, with additional milestone and royalty payments structured around development, regulatory, and sales achievements.

• Collaboration and licensing agreements provide additional funding.

• Strong cash position supports continued pipeline execution.

• Royalties are tiered based on annual net sales, with rates adjusted for biosimilar competition, patent expiry, and compulsory licenses, and subject to minimum royalty floors.

• Cash, cash equivalents, and short-term investments totaled $956.4 million as of March 31, 2026.